Reports Q3 revenue $78.0M, consensus $75.3M. “Our solid third quarter results reflect successful execution of our global commercial strategies,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GKOS:
- Piper says WPS update ‘massive blow’ to Sight Sciences, good news for Glaukos
- Needham medtech/diagnostics analysts hold analyst/industry conference call
- Glaukos management to meet with BTIG
- Sight Sciences price target lowered to $5 from $11 at Stifel
- Stifel sees ‘flurry of potential near-to-intermediate-term drivers’ for Glaukos
